SecBot SecBot
8-K ·Filed Jul 23, 2026

OTLK

Outlook Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed3mo ago SEC0001104659-26-086406
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

The filing itself is routine compensation. The key catalyst is the FDA decision on ONS-5010 due by July 31, the cash bonuses are a direct signal management expects a favorable ruling. Monitor for the FDA action; a positive decision would be a major catalyst, while a negative one removes the bonus trigger and is bearish.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.41
T+0 close · Jul 23, 2026 · via day close
Latest settled
−64.91%
T+60 · $0.4930
Vs SPY
−68.64%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 24 $1.41entry
  2. T+1 · 4mo ago −24.20%α −24.22% · $1.07
  3. T+5 · 4mo ago −25.98%α −26.35% · $1.04
  4. T+20 · 3mo ago −53.94%α −57.56% · $0.6472
  5. T+60 · 29d ago −64.91%α −68.64% · $0.4930
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Outlook Therapeutics granted stock options to its CEO (100,000 options) and CFO (210,078 options) at $1.4304/share, vesting in July 2027, and approved cash bonuses of $420,000 (CEO) and $200,000 (CFO) contingent on FDA approval of ONS-5010 by July 31, 2026. This is a routine compensatory arrangement tied to the BLA process, not a departure or material change in leadership, and carries no immediate financial impact for shareholders beyond the potential cash payout if the FDA milestone is met within days.

Key Facts

  • CEO Robert C. Jahr received 100,000 stock options at $1.4304/share, vesting July 21, 2027.
  • CFO Lawrence A. Kenyon received 210,078 stock options at $1.4304/share, vesting July 21, 2027.
  • CEO awarded a cash bonus opportunity of $420,000, payable only if FDA approves ONS-5010 by July 31, 2026.
  • CFO awarded a cash bonus opportunity of $200,000, payable only if FDA approves ONS-5010 by July 31, 2026.
  • Bonuses are contingent on FDA approval of ONS-5010 (bevacizumab-vikg) by July 31, 2026, and continued service through payment date.
  • Options granted under the 2024 Equity Incentive Plan in recognition of 2025 and 2026 BLA efforts.

Financial Impact

Up to $620,000 in cash bonuses contingent on FDA approval by July 31, 2026; option grants have no immediate cash impact.

dilutioncompensation expense

Risk Factors

  • FDA may not approve ONS-5010 by July 31, 2026, rendering bonuses unearned.
  • Stock price remains near $1.43, with Nasdaq minimum bid price compliance risk noted in the recent DEFA14A.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
70% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-086406
Document: 0001104659-26-086406-index-headers.html0001104659-26-086406
Document: 0001104659-26-086406-index.html0001104659-26-086406
Document: 0001104659-26-086406.txt0001104659-26-086406

Track record

37 reports on OTLK

Performance horizon

13 of 23 bullish or bearish reports moved the stock their way by T+5. Best: +306.25% at T+20 after the May 26, 2026 report. 18 of 23 went positive at some point.

Filters
  1. Oct 13, 20264w ago SC 13G Neutral 4/10 Entry $0.5638 to $0.5200 Now $0.3960 −29.76% ▼ −7.77% −6.62% vs SPY
  2. Oct 6, 20265w ago Press Release Neutral 3/10 Entry $0.5720 to $0.5638 Now $0.3960 −30.77% ▼ −1.43% −1.29% vs SPY
  3. Sep 18, 20268w ago 8-K Neutral 3/10 Entry $0.6863 to $0.6211 Now $0.3960 −42.30% ▼ −9.50% −8.48% vs SPY
  4. Aug 14, 202613w ago 8-K Bearish 6/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
  5. Aug 14, 202613w ago 424B5 Bearish 7/10 Entry $0.7564 to $0.6472 Now $0.3960 +47.65% ▲ +14.44% +13.07% vs SPY
  6. Aug 14, 202613w ago 8-K Bearish 6/10 No price data
  7. Aug 14, 202613w ago Press Release Mixed 7/10 Entry $0.7564 to $0.6472 Now $0.3960 −47.65% ▼ −14.44% −13.07% vs SPY
  8. Aug 12, 202613w ago Press Release Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
  9. Aug 12, 202613w ago 8-K Bearish 7/10 Entry $0.8888 to $0.6763 Now $0.3960 +55.45% ▲ +23.91% +21.94% vs SPY
  10. Jul 24, 202616w ago 8-K Bullish 8/10 Entry $1.07 to $0.9766 Now $0.3960 −62.82% ▼ −8.30% −9.37% vs SPY
Showing 10 of 37

US Market Status

Market Closed · Opens in 6h 5m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 24, 2026